Please assess the completion status of the following clinical trial:

Trial Title: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, aged 18 and older~* Biopsy-proven metastatic carcinoid tumor of the gastrointestinal (GI) tract with disease extent confirmed by computed tomography (CT), magnetic resonance imaging (MRI), or radionuclide imaging~* Symptomatic carcinoid syndrome (≥4 bowel movements per day)~* Ability to provide written informed consent~Exclusion Criteria:~* ≥ 12 high-volume, watery bowel movements per day~* Sponsor-unacceptable clinical laboratory values for hematology and liver function tests at screening~* Karnofsky status ≤70% - unable to care for self~* Surgery within 60 days prior to screening~* A history of short bowel syndrome~* Life expectancy \< 12 months~* History of substance or alcohol abuse within 2 years prior to screening~* Administration of any investigational drug within 30 days of screening or any therapeutic protein or antibody within 90 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telotristat etiprate - Core Phase (Type: EXPERIMENTAL): Following a 2-week Run-In Period, participants received telotristat etiprate capsules at a starting dose of 150 mg, orally three times daily (TID) for 14 days in the Core Phase. Dose escalations (250 mg, 350 mg, 500 mg) occurred serially every 14 days, up to a maximum dosage of telotristat etiprate 500 mg TID, as guided by specific clinical criteria for dose escalation. Upon completion of 12 weeks of treatment, participants were eligible to receive telotristat etiprate in the optional Open-label Extension Period.
- Telotristat etiprate - Extension Period (Type: EXPERIMENTAL): Participants received telotristat etiprate at their highest tolerated dose (250 mg or 500 mg), orally, TID for 124 weeks in the Open-label Extension Period. If neither dose was tolerated participants were discontinued from the study and completed the 2-week Follow-up Visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).